February 13, 2020 / 2:22 PM / 3 days ago

BRIEF-Seattle Genetics Says FDA Accepts Priority Review Of Tucatinib New Drug Application

Feb 13 (Reuters) - Seattle Genetics Inc:

* SEATTLE GENETICS ANNOUNCES FDA FILING ACCEPTANCE FOR PRIORITY REVIEW OF TUCATINIB NEW DRUG APPLICATION (NDA) FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER

* SEATTLE GENETICS INC - UNDER PRESCRIPTION DRUG USER FEE ACT (PDUFA), FDA HAS SET A TARGET ACTION DATE OF AUGUST 20, 2020 FOR TUCATINIB Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below